Image
Image
Select project titles to get information on the abstracts, budgets, publications, patents, and contact information associated with each CounterACT-supported grant from the NIH RePORTER database.
Sort table by any column by clicking the header.
File
| Grant Type | Toxidrome (category) | Title | PI / Project Lead | Institution |
|---|---|---|---|---|
| U54 | Metabolic/Cellular Poison | Advancing novel cyanide countermeasures | MACRAE, CALUM A | BRIGHAM AND WOMEN'S HOSPITAL |
| U54 | Nerve Agent | Novel Anticonvulsant and Neuroprotective Therapies for TETS and OP Intoxication | LEIN, PAMELA J | UNIVERSITY OF CALIFORNIA AT DAVIS |
| U54 | Pulmonary Agent | Development of antidotes for toxic gases | WHITE, CARL W | UNIVERSITY OF COLORADO DENVER |
| U54 | Vesicating Agent | Rutgers University CounterACT Center of Excellence | LASKIN, JEFFREY D | RBHS-SCHOOL OF PUBLIC HEALTH |
| U54 | Vesicating Agent | Barrier Damage and The Immune Cascade Northwestern University CounterACT Center of Excellence (NUCCX) | LU, KURT | NORTHWESTERN UNIVERSITY AT CHICAGO |
| U54 | Vesicating Agent | UAB Research Center of Excellence in Arsenicals | ATHAR, MOHAMMAD | UNIVERSITY OF ALABAMA AT BIRMINGHAM |
| U01 | Metabolic/Cellular Poison | Cyanide/Azide Detoxification by New Cobalt Complexes and NO Donors | PETERSON, JAMES | UNIVERSITY OF PITTSBURGH AT PITTSBURGH |
| U01 | Metabolic/Cellular Poison | Optimization of a Combined Drug and Delivery Device for Treatment of Cyanide Poisoning | PATTERSON, STEVEN E | UNIVERSITY OF MINNESOTA |
| U01 | Nerve Agent | Identification of Novel Brain-penetrating Phenoxyalkyl Pyridinium Oxime Countermeasures | CHAMBERS, JANICE ELAINE | MISSISSIPPI STATE UNIVERSITY |
| U01 | Nerve Agent | Saracatinib and 1400W Counteract Nerve Agents-induced Long-term Neurotoxicity | THIPPESWAMY, THIMMASETTAPPA | IOWA STATE UNIVERSITY |
| U01 | Nerve Agent | Antiglutamatergic Therapy to Protect the Immature Brain Against Nerve Agents | BRAGA, MARIA F | HENRY M. JACKSON FDN FOR THE ADV MIL/MED |
| U01 | Nerve Agent | Novel Water-Soluble Adjunct Anticonvulsants for Nerve Agents | REDDY, DOODIPALA SAMBA | TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR |
| U01 | Nerve Agent | Novel Antibody-Oxime Pairing to Reduce Circulating Organophosphate Levels. | THOMPSON, CHARLES MARK | HUMAN BIOMOLECULAR RESEARCH INSTITUTE |
| U01 | Nerve Agent | Anticholinergic and antiepileptic Therapies for Chlorine Toxicity | VERESS, LIVIA AGNES | UNIVERSITY OF COLORADO DENVER |
| U01 | Nerve Agent | Development of IM Formulation of (2S,3S)-SPD for Nerve Agent Seizures | ROGAWSKI, MICHAEL A | UNIVERSITY OF CALIFORNIA AT DAVIS |
| U01 | Nerve Agent | Novel Counteract Agents To Reduce Mortality And Morbidity Following Organophosphate Status Epilepticus | DELORENZO, ROBERT JOHN | VIRGINIA COMMONWEALTH UNIVERSITY |
| U01 | Nerve Agent | Novel pediatric anticonvulsants for nerve agents | REDDY, DOODIPALA SAMBA | TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR |
| U01 | Nerve Agent | Optimization of Substituted Phenoxyalkyl Pyridinium Oximes as Therapies for Organophosphate Poisoning | CHAMBERS, JANICE ELAINE | MISSISSIPPI STATE UNIVERSITY |
| U01 | Nerve Agent | Advanced Development of Drugs to Mitigate Parathion Intoxication | LASKIN, JEFFREY D | RBHS-SCHOOL OF PUBLIC HEALTH |
| U01 | Nerve Agent | Improved Therapeutics for the Resurrection of the Aged Form of Acetylcholinesterase | HADAD, CHRISTOPHER M | OHIO STATE UNIVERSITY |
| U01 | Pharmaceutical-based Agent | Immunotherapy to Counteract Lethal Doses of Carfentanil | JANDA, KIM | SCRIPPS RESEARCH INSTITUTE |
| U01 | Pharmaceutical-based Agent | Antibody-based countermeasures against fentanyl and its analogues | PRAVETONI, MARCO | UNIVERSITY OF MINNESOTA |
| U01 | Pharmaceutical-based Agent | Development of Agents for Synthetic Opioid Overdose | PRISINZANO, THOMAS EDWARD | UNIVERSITY OF KENTUCKY |
| U01 | Pharmaceutical-based Agent | Optimization of novel thioesters as a therapeutic strategy for combating opioid overdoses and abuse | LEWIS, STEPHEN JOHN | CASE WESTERN RESERVE UNIVERSITY |
| U01 | Pulmonary Agent | CIALIS® reverses halogen induced injury to pregnant animals and their offspring | MATALON, SADIS | UNIVERSITY OF ALABAMA AT BIRMINGHAM |
| U01 | Pulmonary Agent | Optimization of AEOL10150 treatment of sulfur mustard-induced lung toxidrome in a pig model | DAY, BRIAN J | NATIONAL JEWISH HEALTH |
| U01 | Pulmonary Agent | Advanced TRPA1 Inhibitor for the Treatment of Chlorine Inhalation Injury | JORDT, SVEN-ERIC | DUKE UNIVERSITY |
| U01 | Pulmonary Agent | Identification of AMD3100 (Plerixafor) as a potential lead compound for chlorine toxicity | AGGARWAL, SAURABH | UNIVERSITY OF ALABAMA AT BIRMINGHAM |
| U01 | Pulmonary Agent | Functional Genomics of Chemical-Induced Acute Lung Injury | LEIKAUF, GEORGE DOUGLAS | UNIVERSITY OF PITTSBURGH AT PITTSBURGH |
| U01 | Pulmonary Agent | Antidotes against HCI-induced chronic lung injury | CATRAVAS, JOHN D | OLD DOMINION UNIVERSITY |
| U01 | Vesicating Agent | Optimization of Novel Molecular Target-based Drugs for Arsenical Skin Injury | ATHAR, MOHAMMAD | UNIVERSITY OF ALABAMA AT BIRMINGHAM |
| U01 | Vesicating Agent | Targeted Therapeutic Approaches to Counteract Toxicity from Phosgene Oxime Skin Exposure | TEWARI-SINGH, NEERA | MICHIGAN STATE UNIVERSITY |
| U01 | Vesicating Agent | Translation of novel and repurposed drugs to address the acute and late effects of mustard exposure | LU, KURT | NORTHWESTERN UNIVERSITY AT CHICAGO |
| U01 | Vesicating Agent | Identification of lead compounds to topically treat sulfur mustard injury to reduce ocular damage and improve vision. | BAKER, SHENDA | SYNEDGEN, INC. |
| U01 | Vesicating Agent | Dexamethasone as an Effective Therapy for Ocular Injuries by Vesicating Agents. | AGARWAL, RAJESH | UNIVERSITY OF COLORADO DENVER |
| U01 | Vesicating Agent | Turbo Eye Drops to Treat Ocular Toxicity and Blindness from Sulfur Mustard | MOHAN, RAJIV RAVINDRA | UNIVERSITY OF MISSOURI-COLUMBIA |
| T32 | Metabolic/Cellular Poison | Molecular Mechanisms of Environmental Injury | AMEREDES, BILL T | UNIVERSITY OF TEXAS MED BR GALVESTON |
| R21 | Metabolic/Cellular Poison | Novel therapeutic targets for fluoroacetate-induced toxicities. | AHMAD, AFTAB | UNIVERSITY OF ALABAMA AT BIRMINGHAM |
| R21 | Metabolic/Cellular Poison | Hydrogen sulfide toxicity to the cornea | BALNE, PRAVEEN K | UNIVERSITY OF MISSOURI-COLUMBIA |
| R21 | Metabolic/Cellular Poison | Treatment strategies for ocular toxicity from chloropicrin | TEWARI-SINGH, NEERA | MICHIGAN STATE UNIVERSITY |
| R21 | Metabolic/Cellular Poison | Novel Antidotes for H2S Poisoning | ICHINOSE, FUMITO | MASSACHUSETTS GENERAL HOSPITAL |
| R21 | Metabolic/Cellular Poison | The cyclic redox dye Azure B as a novel cyanide antidote: in vivo efficacy studies | HAOUZI, PHILIPPE A | PENNSYLVANIA STATE UNIV HERSHEY MED CTR |
| R21 | Nerve Agent | Saracatinib Mitigates OP nerve agent-induced Long-term Neurotoxicity | THIPPESWAMY, THIMMASETTAPPA | IOWA STATE UNIVERSITY |
| R21 | Nerve Agent | Soman-induced neuropathology in Gottingen minipig: large animal model assessment for MCM | LANGE, LUCILLE | GENEVA FOUNDATION |
| R21 | Nerve Agent | Mitoapocynin, a novel NOX2 inhibitor, mitigates nerve agents induced longterm neurotoxicity | THIPPESWAMY, THIMMASETTAPPA | IOWA STATE UNIVERSITY |
| R21 | Nerve Agent | Identifying Molecular Targets for the Proconvulsant Activity of TETS | LEIN, PAMELA J | UNIVERSITY OF CALIFORNIA AT DAVIS |
| R21 | Pharmaceutical-based Agent | Safer, Non-addicting Pain Management: Identification and Expression of Cyclic Peptides with Analgesic and Breathing Stimulant Properties | COTTEN, JOSEPH F | MASSACHUSETTS GENERAL HOSPITAL |
| R21 | Pharmaceutical-based Agent | Covalent Naloxone Nanoparticles for Next Generation Fentanyl Countermeasures | AVERICK, SAADYAH | ALLEGHENY-SINGER RESEARCH INSTITUTE |
| R21 | Pharmaceutical-based Agent | Microneedles for emergency treatment of synthetic opioid overdose | NARAYAN, ROGER J | NORTH CAROLINA STATE UNIVERSITY RALEIGH |
| R21 | Pulmonary Agent | Inhibition of soluble epoxide hydrolase protects against phosgene-induced lung injuries | ACHANTA, SATYANARAYANA | DUKE UNIVERSITY |
| R21 | Pulmonary Agent | Cannabinoid-2 receptor signaling in vesicant induced lung injury | NAGRE, NAGARAJA | EASTERN VIRGINIA MEDICAL SCHOOL |
| R21 | Pulmonary Agent | Mitigation of Chlorine Injury to Mitochondria | MATALON, SADIS | UNIVERSITY OF ALABAMA AT BIRMINGHAM |
| R21 | Pulmonary Agent | Esomeprazole counteracts chlorine toxicity in pregnant animals | JILLING, TAMAS | UNIVERSITY OF ALABAMA AT BIRMINGHAM |
| R21 | Pulmonary Agent | Airway stem cell activation in the mitigation of halogen-induced lung injury | AHMAD, SHAMA | UNIVERSITY OF ALABAMA AT BIRMINGHAM |
| R21 | Pulmonary Agent | Repurposing thiosulfate for chlorine gas exposure | DAY, BRIAN J | NATIONAL JEWISH HEALTH |
| R21 | Pulmonary Agent | Chlorinated lipid modification of proteins: Biomarkers of chlorine gas exposure | FORD, DAVID A | SAINT LOUIS UNIVERSITY |
| R21 | Pulmonary Agent | Specialized pro-resolving mediators as potential medical countermeasures in a pig model of chlorine gas-induced acute lung injury | ACHANTA, SATYANARAYANA | DUKE UNIVERSITY |
| R21 | Vesicating Agent | MicroRNAs in Skin Inflammation and Wounding by Mustard Vesicants. | AGARWAL, RAJESH | UNIVERSITY OF COLORADO DENVER |
| R21 | Vesicating Agent | Imaging the healing of ocular injury caused by vesicants to identify new therapies | WOLLMAN, ROY | UNIVERSITY OF CALIFORNIA LOS ANGELES |
| R21 | Vesicating Agent | Targeting Citrullination in Ocular Chemical Injury | MOHAN, ROYCE | UNIVERSITY OF CONNECTICUT SCH OF MED/DNT |
| R03 | Nerve Agent | A novel mouse model for anxiety-induced seizures | BRENNER, ROBERT | UNIVERSITY OF TEXAS HLTH SCIENCE CENTER |
| R01 | Nerve Agent | Functional analysis of the microRNA-induced silencing complex in epilepsy | GROSS, CHRISTINA | CINCINNATI CHILDRENS HOSP MED CTR |
| R01 | Pulmonary Agent | Novel ARNT-mediated Regulatory Paradigm of AHR Signaling | WRIGHT, CASEY W | UNIVERSITY OF TEXAS MED BR GALVESTON |
| R01 | Pulmonary Agent | COUNTERACT Supplement--ASPIRE: Air Pollution: Strategies for Personalized Intervention to Reduce Exposure | RAJAGOPALAN, SANJAY | CASE WESTERN RESERVE UNIVERSITY |
| R01 | Vesicating Agent | NOT-NS-20-030: Use of anchored biologics to treat vesicant induced neovascularization | SHANKS, ROBERT M | UNIVERSITY OF PITTSBURGH AT PITTSBURGH |
| R01 | Vesicating Agent | Clusterin at the Ocular Surface Administrative Supplement II | FINI, M ELIZABETH | TUFTS MEDICAL CENTER |
| F30 | Vesicating Agent | Characterization of an Ex Vivo Bioprinted Skin Model of Sulfur Mustard Injury | JORGENSEN, ADAM | WAKE FOREST UNIVERSITY HEALTH SCIENCES |